Global LNP-mRNA Therapy Market to Grow at a CAGR of 6.1% from 2025 to 2032 – Key Players to Watch According to a new report from Intel Market Research, Global LNP-mRNA Therapy market was valued at USD 500 million in 2025 and is projected to reach USD 719 million by 2032, growing at a CAGR of 6.1% during the forecast period (2026–2032). This growth is propelled by the success of mRNA-based COVID-19 vaccines, increasing investments in genetic medicine infrastructure, and expansion into non-vaccine therapeutic applications. What is LNP-mRNA Therapy? LNP-mRNA Therapy represents a breakthrough biomedical approach combining lipid nanoparticles (LNPs) with messenger RNA to enable targeted protein production in cells. These therapies utilize LNPs as delivery vehicles that protect mRNA molecules from degradation while facilitating cellular uptake. Once delivered, the mRNA instructs cells to produce therapeutic proteins, offering potential treatments for cancer, genetic disorders, and infectious diseases. The technology gained global recognition through COVID-19 vaccines from Moderna and Pfizer-BioNTech, demonstrating unprecedented efficacy and scalability. Current applications extend beyond vaccines to include oncology treatments, protein replacement therapies, and genetic disorder corrections, positioning LNP-mRNA as a versatile platform for modern medicine. 📥 Download Sample Report: https://www.intelmarketresearch.com/download-free-sample/6809/lnp-mrna-therapy-market